JP2017529379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529379A5 JP2017529379A5 JP2017516693A JP2017516693A JP2017529379A5 JP 2017529379 A5 JP2017529379 A5 JP 2017529379A5 JP 2017516693 A JP2017516693 A JP 2017516693A JP 2017516693 A JP2017516693 A JP 2017516693A JP 2017529379 A5 JP2017529379 A5 JP 2017529379A5
- Authority
- JP
- Japan
- Prior art keywords
- degrees
- methyl
- disease
- powder
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1-methyl-1H-pyrazol-4-yl Chemical group 0.000 claims 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 206010057668 Cognitive disease Diseases 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000009471 Gastroesophageal Reflux Diseases 0.000 claims 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 206010043234 Tendon disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 201000006180 eating disease Diseases 0.000 claims 1
- 201000006860 gastroesophageal reflux disease Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
Claims (8)
- ８．１３±０．２度（２θ）および１８．３９±０．２度（２θ）でのピークを含む、銅Ｘ線源を使用して得られる粉末Ｘ線回折パターンによって特徴付けられる、結晶形の１−（１−メチル−１Ｈ−ピラゾール−４−イル）−Ｎ−（（１Ｒ，５Ｓ，７Ｓ）−９−メチル−３−オキサ−９−アザビシクロ［３．３．１］ノナン−７−イル）−１Ｈ−インドール−３−カルボキサミド。
- 前記粉末Ｘ線回折パターンが、１７．０１±０．２度（２θ）、１７．４９±０．２度（２θ）、および２０．９１±０．２度（２θ）から選択される１つ以上のピークをさらに含む、請求項１に記載の結晶形。
- 前記粉末Ｘ線回折パターンが、１７．０１±０．２度（２θ）、１７．４９±０．２度（２θ）、および２０．９１±０．２度（２θ）から選択される２つ以上のピークをさらに含む、請求項１に記載の結晶形。
- 前記粉末Ｘ線回折パターンが、８．１３±０．２度（２θ）、１７．０１±０．２度（２θ）、１７．４９±０．２度（２θ）、１８．３９±０．２度（２θ）、および２０．９１±０．２度（２θ）でのピークを含む、請求項１に記載の結晶形。
- 請求項１〜４のいずれか一項に記載の結晶形の１−（１−メチル−１Ｈ−ピラゾール−４−イル）−Ｎ−（（１Ｒ，５Ｓ，７Ｓ）−９−メチル−３−オキサ−９−アザビシクロ［３．３．１］ノナン−７−イル）−１Ｈ−インドール−３−カルボキサミドと、医薬として許容し得る賦形剤とを含む医薬組成物。
- 請求項１〜４のいずれか一項に記載の治療有効量の結晶形の１−（１−メチル−１Ｈ−ピラゾール−４−イル）−Ｎ−（（１Ｒ，５Ｓ，７Ｓ）−９−メチル−３−オキサ−９−アザビシクロ［３．３．１］ノナン−７−イル）−１Ｈ−インドール−３−カルボキサミドを含有する、対象における５−ＨＴ３受容体アンタゴニストの投与によって治療可能である疾患の治療剤。
- 前記疾患が、嘔吐、片頭痛、物質乱用、物質嗜癖、不安、抑うつ、摂食障害、統合失調症、統合失調症に伴う認知機能障害、パーキンソン病、ハンチントン舞踏病、初老期認知症、アルツハイマー病、疼痛、消化不良、胃食道逆流症、過敏性腸症候群、アテローム性動脈硬化症、腱障害、および線維筋痛症から選択される、請求項６に記載の治療剤。
- 前記疾患が、統合失調症に伴う認知機能障害である、請求項６に記載の治療剤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021188428A JP2022036978A (ja) | 2014-09-29 | 2021-11-19 | 結晶形の１－（１－メチル－１ｈ－ピラゾール－４－イル）－ｎ－（（１ｒ，５ｓ，７ｓ）－９－メチル－３－オキサ－９－アザビシクロ［３．３．１］ノナン－７－イル）－１ｈ－インドール－３－カルボキサミド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056982P | 2014-09-29 | 2014-09-29 | |
| US62/056,982 | 2014-09-29 | ||
| PCT/US2015/052806 WO2016053947A1 (en) | 2014-09-29 | 2015-09-29 | Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021188428A Division JP2022036978A (ja) | 2014-09-29 | 2021-11-19 | 結晶形の１－（１－メチル－１ｈ－ピラゾール－４－イル）－ｎ－（（１ｒ，５ｓ，７ｓ）－９－メチル－３－オキサ－９－アザビシクロ［３．３．１］ノナン－７－イル）－１ｈ－インドール－３－カルボキサミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529379A JP2017529379A (ja) | 2017-10-05 |
| JP2017529379A5 true JP2017529379A5 (ja) | 2018-11-08 |
| JP7055017B2 JP7055017B2 (ja) | 2022-04-15 |
Family
ID=54289137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516693A Active JP7055017B2 (ja) | 2014-09-29 | 2015-09-29 | 結晶形の１－（１－メチル－１ｈ－ピラゾール－４－イル）－ｎ－（（１ｒ，５ｓ，７ｓ）－９－メチル－３－オキサ－９－アザビシクロ［３．３．１］ノナン－７－イル）－１ｈ－インドール－３－カルボキサミド |
| JP2021188428A Withdrawn JP2022036978A (ja) | 2014-09-29 | 2021-11-19 | 結晶形の１－（１－メチル－１ｈ－ピラゾール－４－イル）－ｎ－（（１ｒ，５ｓ，７ｓ）－９－メチル－３－オキサ－９－アザビシクロ［３．３．１］ノナン－７－イル）－１ｈ－インドール－３－カルボキサミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021188428A Withdrawn JP2022036978A (ja) | 2014-09-29 | 2021-11-19 | 結晶形の１－（１－メチル－１ｈ－ピラゾール－４－イル）－ｎ－（（１ｒ，５ｓ，７ｓ）－９－メチル－３－オキサ－９－アザビシクロ［３．３．１］ノナン－７－イル）－１ｈ－インドール－３－カルボキサミド |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10329306B2 (ja) |
| EP (1) | EP3201203B1 (ja) |
| JP (2) | JP7055017B2 (ja) |
| CN (1) | CN106795172B (ja) |
| CA (1) | CA2962429C (ja) |
| DK (1) | DK3201203T3 (ja) |
| ES (1) | ES2883295T3 (ja) |
| HU (1) | HUE055175T2 (ja) |
| MA (1) | MA40771B1 (ja) |
| PL (1) | PL3201203T3 (ja) |
| PT (1) | PT3201203T (ja) |
| WO (1) | WO2016053947A1 (ja) |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| FR2531083B1 (fr) | 1982-06-29 | 1986-11-28 | Sandoz Sa | Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments |
| JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
| DE3687080T2 (de) | 1985-04-27 | 1993-03-25 | Beecham Group Plc | Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung. |
| GB8510752D0 (en) | 1985-04-27 | 1985-06-05 | Beecham Group Plc | Compounds |
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| DE3722069A1 (de) | 1986-08-21 | 1988-02-25 | Toyoda Gosei Kk | Signalhornschaltvorrichtung fuer ein steuerrad |
| ES2036587T5 (es) | 1986-11-21 | 1995-10-16 | Glaxo Group Ltd | Medicamentos para el tratamiento o prevencion del sindrome de abstinencia. |
| IT1226389B (it) | 1988-07-12 | 1991-01-15 | Angeli Inst Spa | Nuovi derivati ammidinici e guanidinici |
| GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
| JPH0421681A (ja) | 1990-05-14 | 1992-01-24 | Fujisawa Pharmaceut Co Ltd | ピロロピリジン誘導体 |
| US5187166A (en) | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| JP3251954B2 (ja) | 1990-07-31 | 2002-01-28 | 日清ファルマ株式会社 | アザビシクロ誘導体 |
| HU211081B (en) | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5149962A (en) | 1991-06-03 | 1992-09-22 | Simmonds Precision Products, Inc. | Proximity detector using faraday effect and bidirectional transmission |
| US5344831A (en) | 1992-01-31 | 1994-09-06 | Nisshin Flour Milling Co., Ltd. | Diazabicyclo derivatives |
| GB9216154D0 (en) | 1992-07-30 | 1992-09-09 | Glaxo Group Ltd | Chemical compounds |
| GB9406857D0 (en) | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| WO1996012722A1 (fr) | 1994-10-20 | 1996-05-02 | Nisshin Flour Milling Co., Ltd. | Agoniste des recepteurs 5-ht¿4? |
| US5684003A (en) | 1994-10-20 | 1997-11-04 | Nisshin Flour Milling Co., Ltd. | 5-HT4 receptor agonists |
| JP3904254B2 (ja) | 1994-10-20 | 2007-04-11 | 株式会社日清製粉グループ本社 | ５−ｈｔ４受容体作動薬 |
| AU2319100A (en) | 1999-01-28 | 2000-08-18 | Nippon Shinyaku Co. Ltd. | Amide derivatives and drug compositions |
| WO2001043746A1 (fr) | 1999-12-14 | 2001-06-21 | Nippon Shinyaku Co., Ltd. | Composition medicinale |
| EP1427707A1 (en) | 2001-09-19 | 2004-06-16 | Pharmacia Corporation | Substituted indazole compounds for the treatment of inflammation |
| US20040038958A1 (en) | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| PL210065B1 (pl) | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków |
| EP1558081A4 (en) | 2003-01-13 | 2006-06-14 | Dynogen Pharmaceuticals Inc | METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS |
| WO2004089470A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | New amide derivatives and pharmaceutical use thereof |
| CN101001856A (zh) | 2004-03-25 | 2007-07-18 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
| KR101176670B1 (ko) | 2004-03-25 | 2012-08-23 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도 |
| US20090042949A1 (en) | 2005-01-19 | 2009-02-12 | Benjamin Pelcman | Indoles Useful in the Treatment of Inflammation |
| WO2007038367A1 (en) | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| CN101460458A (zh) | 2006-02-15 | 2009-06-17 | 阿勒根公司 | 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物 |
| NZ570528A (en) | 2006-02-15 | 2011-09-30 | Allergan Inc | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| KR101288781B1 (ko) | 2006-06-28 | 2013-07-22 | 암젠 인크 | 글리신 수송자-1 억제제 |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| EP2114876A4 (en) | 2007-02-05 | 2010-12-22 | Amira Pharmaceuticals Inc | INVERSE INDOLES AS INHIBITORS OF THE 5-LIPOXYGENASE ACTIVATION PROTEIN (FLAP) |
| MX2009008439A (es) | 2007-02-12 | 2009-08-13 | Intermune Inc | Nuevos inhibidores de la replicacion del virus de hepatitis c. |
| AU2008286946B2 (en) | 2007-08-10 | 2013-11-21 | H. Lundbeck A/S | Heteroaryl amide analogues |
| WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| KR101653707B1 (ko) | 2008-05-29 | 2016-09-02 | 알바니 몰레큘라 리써치, 인크. | 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도 |
| TWI429628B (zh) | 2010-03-29 | 2014-03-11 | Univ Taipei Medical | 吲哚基或吲哚啉基羥肟酸化合物 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
-
2015
- 2015-09-29 US US15/515,263 patent/US10329306B2/en active Active
- 2015-09-29 MA MA40771A patent/MA40771B1/fr unknown
- 2015-09-29 HU HUE15778162A patent/HUE055175T2/hu unknown
- 2015-09-29 PL PL15778162T patent/PL3201203T3/pl unknown
- 2015-09-29 DK DK15778162.6T patent/DK3201203T3/da active
- 2015-09-29 JP JP2017516693A patent/JP7055017B2/ja active Active
- 2015-09-29 EP EP15778162.6A patent/EP3201203B1/en active Active
- 2015-09-29 CA CA2962429A patent/CA2962429C/en active Active
- 2015-09-29 PT PT157781626T patent/PT3201203T/pt unknown
- 2015-09-29 ES ES15778162T patent/ES2883295T3/es active Active
- 2015-09-29 CN CN201580052611.3A patent/CN106795172B/zh active Active
- 2015-09-29 WO PCT/US2015/052806 patent/WO2016053947A1/en active Application Filing
-
2021
- 2021-11-19 JP JP2021188428A patent/JP2022036978A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503010A5 (ja) | ||
| EA201401150A1 (ru) | Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств | |
| JP2008519794A5 (ja) | ||
| NZ595307A (en) | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use | |
| JP2018168191A5 (ja) | ||
| PH12015500460B1 (en) | Coated pharmaceutical composition containing regorafenib | |
| HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
| JP2012176975A5 (ja) | ||
| HRP20171793T1 (hr) | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata | |
| IL204064A (en) | Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists | |
| JP2012512158A5 (ja) | ||
| JP2018090566A5 (ja) | ||
| EA023293B1 (ru) | ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ | |
| JP2008110970A5 (ja) | ||
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| MX2010012189A (es) | Derivados de quinuclidina como antagonistas del receptor m3 muscarinico. | |
| AU2012277905A8 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| JP2013538206A5 (ja) | ||
| JP2013531073A5 (ja) | ||
| CL2007002768A1 (es) | Compuestos derivados de quinolin-amina; proceso de preparacion de dichos compuestos; medicamento; y uso para el tratamiento de enfermedades tales como depresion, trastornos de ansiedad, esquizofrenia, agorafobia, dolor, demencia y enfermedad de parki | |
| BR112013018296A2 (pt) | tratamento de disfunções cognitivas em esquizofrenia | |
| NZ761037A (en) | New uses of a pure 5-ht6 receptor antagonist | |
| JP2007197423A5 (ja) | ||
| JP2017529379A5 (ja) | ||
| PH12016500197A1 (en) | Novel biphenyl derivative and method for preparing same |